← Back to Treatments
🏅 FDA Orphan Designation

Rebyota

fecal microbiota, live - jslm

Manufacturer: Ferring Pharmaceuticals, Inc.

Indicated for:
Autoimmune lymphoproliferative syndrome-recurrent viral infections due to CASP8 deficiencyOrphanCoccidioidomycosisCombined immunodeficiency due to IL21R deficiency

FDA-Approved Indications (3)

prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI.

Population: individuals 18 years of age and older

REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI.

Population: individuals 18 years of age and older

Indications & Usage

1 INDICATIONS AND USAGE REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. ( 1 ) Limitation of Use: REBYOTA is not indicated for treatment of CDI. Limitation of Use: REBYOTA is not indicated for treatment of CDI.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.